ReviewFrontiers in immunology2026
ILC imbalance - a new piece in the gut-kidney axis puzzle.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The progression of chronic kidney disease (CKD) is closely linked to gut microbiota dysbiosis and the consequent accumulation of harmful microbial metabolites, forming a vicious cycle called "gut-kidney axis." However, the specific immune mechanisms connecting these alterations in the gut milieu to renal inflammation remain poorly defined. Innate lymphoid cells (ILCs), with their tissue-resident nature, plasticity, and potential migratory capacity, are poised to be critical mediators in this process. Objective: This review aims to systematically elucidate the mechanisms by which ILCs, in response to gut-derived metabolic signals, regulate kidney disease through the gut-kidney axis. Methods: We synthesized evidence from both preclinical and clinical studies, with a focus on: ① the functions of distinct ILC subsets in kidney disease; ② the dual effects-detrimental or protective-of individual ILC subsets and their secreted factors on renal function and morphology; ③ experimental evidence linking ILC activity to the disruption of gut-kidney homeostasis. Conclusion: We propose that ILC dysregulation represents a novel immune mechanism underpinning "microbiota-gut-kidney axis" dysfunction. This review integrates existing evidence to formulate a central working model that positions the aryl hydrocarbon receptor (AHR) as a pivotal node connecting gut microbial metabolism to ILC-mediated immunity in the kidney. The trans-tissue migration of ILCs, their sensing of uremic toxins (e.g., indoxyl sulfate and kynurenine), and their synergy with adaptive immunity collectively contribute to renal injury. Future research should focus on developing novel therapeutic strategies that target the gut microbiota-ILC interaction-such as dietary interventions, probiotics, or immunomodulators-for the treatment of kidney diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.